Drugs / anti-CD7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00640497 | Jan 2010 → Jan 2012 | acute graft versus host disease | Henogen | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Imviva Bio | Results ImvivaBio Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress imvivabio.com ↗
The therapy demonstrated an overall response rate of 85.7% (6/7 patients) and an overall complete remission (CRc = CR + CRi) rate of 71.4% (5/7 patients), with 80% (4/5) achieving MRD-negative status. |
| 2026-05-29 | Imviva Bio | Results ImvivaBio to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses imvivabio.com ↗
CTD402 Allogeneic Anti-CD7 CAR T-Cell Therapy is Safe and Effective in Adolescent/Pediatric Patients (pts) with Relapsed/Refractory (R/R) T ALL/LBL |
| 2026-04-02 | Wugen, Inc. | Regulatory Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel wugen.com ↗
Wugen was invited by the FDA to participate in the CDRP program, which selects up to nine development programs annually across the FDA’s two product review centers for biologics and drugs. |
| 2026-01-27 | Imviva Bio | Regulatory ImvivaBio Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma imvivabio.com ↗
ImvivaBio, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to CTD402, the company’s investigational allogeneic anti-CD7 CAR-T cell therapy for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). |
| 2026-01-21 | Wugen, Inc. | Regulatory U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma wugen.com ↗
Breakthrough Therapy Designation is intended to expedite the development and review of medicines for serious or life-threatening conditions with evidence of a substantial clinical improvement. |
| 2025-12-08 | Imviva Bio | Results ImvivaBio Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗
ImvivaBio, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR-T cell therapy, in two oral sessions at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. |
| 2025-12-08 | Imviva Bio | Results Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias presented at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗
Safety was consistent with T-ALL/LBL observations, with manageable cytokine release syndrome and no dose-limiting toxicities or treatment-related deaths, and cytopenia resolved in most responders. |
| 2025-12-05 | Wugen, Inc. | Results Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting wugen.com ↗
In the Phase 1/2 Study, Sofi-cel exhibited over one-hundred-fold expansion following infusion and persisted in circulation for up to three months. |
| 2024-12-05 | Wugen, Inc. | Results Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 wugen.com ↗
Results from Phase 1/2 showed continued anti-leukemic activity and clinically manageable safety in adults and adolescents. |
| 2023-12-11 | Wugen, Inc. | Results Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting wugen.com ↗
In a presentation titled Wugen shared these updated data: “Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),” |
| 2023-06-09 | Wugen, Inc. | Results Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress wugen.com ↗
The Objective Response Rate (ORR) in efficacy evaluable patients was 57% overall (4/7), including 2 Complete Responses (CR), 1 morphological leukemia-free state (MLFS), and 1 Partial Response (PR). |
| 2023-05-11 | Wugen, Inc. | Results Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress wugen.com ↗
The poster presentation includes new clinical data highlighting the promising safety profile of WU-CART-007 and preliminary evidence of anti-leukemic activity in patients with R/R T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). |
| 2022-11-07 | Beam Therapeutics Inc. | Regulatory Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results beamtx.com ↗
Beam has submitted its response to the FDA and will provide an update on next steps, as available. |
| 2020-11-09 | Beam Therapeutics Inc. | Results Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020 beamtx.com ↗
Preclinical data on BEAM-201 are being presented in a poster session during the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), and demonstrate potent, dose-dependent tumor control in vitro and in an in vivo xenograft model. |
| 2019-12-03 | Xenikos | Results Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting xenikos.com ↗ |
All press releases naming this drug 15 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD7 | “the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain” NCT00640497 ↗ |
| Action | Deplete | “both conjugated to a cell-killing toxin” NCT00640497 ↗ |
| Modality | Monoclonal antibody | “a mAb anti-CD7 conjugated to recombinant ricin A chain” NCT00640497 ↗ |